Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 30, 2017 16:00 ET | Source: Pluristem Therapeutics Inc.

Pluristem and Sosei CVC Advancing Towards Finalizing Joint Venture for the Commercialization of PLX-PAD in Japan

HAIFA, Israel, March 30, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI), (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced advancement in...
March 29, 2017 16:00 ET | Source: Pluristem Therapeutics Inc.

Pluristem Launches Co-CEO Structure and Appoints New CFO

Yaky Yanay appointed Co-Chief Executive Officer to serve together with Co-Chief Executive Officer Zami AbermanErez Egozi appointed as Chief Financial Officer HAIFA, Israel, March 29, 2017 (GLOBE...
February 13, 2017 07:00 ET | Source: Pluristem Therapeutics Inc.

Pluristem Reports Second Quarter Fiscal 2017 Highlights & Provides Calendar 2017 Outlook

HAIFA, Israel, Feb. 13, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today reported financial update...
January 25, 2017 16:30 ET | Source: Pluristem Therapeutics Inc.

Pluristem Announces Closing of Bought Offering and Underwriter’s Exercise in Full of Over-Allotment Option

HAIFA, Israel, Jan. 25, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI) announced today that H.C. Wainwright & Co., LLC, the sole book-running manager of its...
January 20, 2017 07:00 ET | Source: Pluristem Therapeutics Inc.

Pluristem Increases Previously Announced Bought Deal Offering of Common Stock and Warrants to $15,000,000

HAIFA, Israel, Jan. 20, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI) announced today that due to increased demand, it has entered into an amended and restated...
January 19, 2017 16:52 ET | Source: Pluristem Therapeutics Inc.

Pluristem Announces Bought Deal Offering

HAIFA, Israel, Jan. 19, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) announced today that it has entered into an underwriting agreement with H.C. Wainwright &...
January 17, 2017 05:30 ET | Source: Pluristem Therapeutics Inc.

Pluristem Receives Clearance from Germany to Initiate its Multinational Phase III Trial in Critical Limb Ischemia Targeting Early Conditional Marketing Approval

PLX-PAD cells could potentially obtain early conditional marketing approval in Europe via the Adaptive Pathways pilot project based on positive interim efficacy data from first 125 patients This...
January 12, 2017 06:00 ET | Source: Pluristem Therapeutics Inc.

Pluristem Completes Patient Enrollment in a Large Multinational Phase II Trial in Intermittent Claudication

Top line results from the 172-patient trial to be reported in early 2018Data to support Pluristem’s planned Biologics License Application for marketing approval of PLX-PAD in the U.S. and Europe14...
January 10, 2017 07:00 ET | Source: Pluristem Therapeutics Inc.

Pluristem’s Phase III Study of PLX-PAD Cells for the Treatment of Critical Limb Ischemia Cleared by U.S. FDA

HAIFA, Israel, Jan. 10, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that the...
December 27, 2016 03:00 ET | Source: Pluristem Therapeutics Inc.

Pluristem and New York Blood Center to Collaborate in Evaluating PLX-R18 as an Adjuvant Therapy to Umbilical Cord Blood Transplantation, Winning $900,000 Funding From BIRD

Prior research has suggested that PLX-R18 helps cord blood cells to engraft more rapidly and effectivelyGrant of $900,000 from Israel-U.S. Binational Industrial Research and Development Foundation...